Prelude Capital Management’s ResMed RMD Stock Holding History

Prelude Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-9,500	Closed	-$589K	–	1735
2016 Q4	$589K	Buy	9,500 +1,800	+23%	+$110K	0.07%	294
2016 Q3	$499K	Buy	+7,700	New	+$513K	0.05%	315

Other funds holding RMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Prelude Capital Management's RMD Position: Q2 2026 in Review

Prelude Capital Management sold out of ResMed (RMD) in Q2 2026, closing a stake of 1,095 shares — an estimated $246K sold.

Prelude Capital Management first reported a position in RMD in Q3 2013 and held it in 16 quarters. The position peaked at $702K in Q1 2021. 889 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

Prelude Capital Management reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
Prelude Capital Management sold 1,095 ResMed shares in Q2 2026, an estimated $246K.
Prelude Capital Management first reported a position in ResMed in Q3 2013 and held it in 16 quarters.
Prelude Capital Management's ResMed position peaked at $702K in Q1 2021.
889 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.